We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

59 hedge funds and large institutions have $172M invested in AEON Biopharma in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 2

36% more capital invested

Capital invested by funds: $126M → $172M (+$45.8M)

26% more funds holding

Funds holding: 47 → 59 (+12)

0.2% more ownership

Funds ownership: 0.59% → 0.79% (+0.2%)

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

Holders
59
Holders Change
+12
Holders Change %
+25.53%
% of All Funds
1.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
7
Reduced
7
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ECP
Empyrean Capital Partners
California
+$13.6M
2
HSBC Holdings
HSBC Holdings
United Kingdom
+$8.73M
3
SCM
Shaolin Capital Management
Florida
+$7.86M
4
Citadel Advisors
Citadel Advisors
Florida
+$4.86M
5
Marshall Wace
Marshall Wace
United Kingdom
+$3.41M

Top Sellers

Rank Fund Capital Flow
1
PAMP
Polar Asset Management Partners
Ontario, Canada
-$2.91M
2
Verition Fund Management
Verition Fund Management
Connecticut
-$2.89M
3
MP
Mangrove Partners
Connecticut
-$91.5K
4
HighTower Advisors
HighTower Advisors
Illinois
-$28.6K
5
WA
Whitebox Advisors
Minnesota
-$23K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACA
26
Arena Capital Advisors
California
$2.43M +$2.42M +3,467 New
Balyasny Asset Management
27
Balyasny Asset Management
Illinois
$1.95M – – –
Millennium Management
28
Millennium Management
New York
$1.92M +$1.01M +1,444 +112%
WAM
29
Wolverine Asset Management
Illinois
$1.72M – – –
State of Wisconsin Investment Board
30
State of Wisconsin Investment Board
Wisconsin
$1.56M +$1.55M +2,222 New
AA
31
AQR Arbitrage
Connecticut
$1.49M +$29.3K +42 +2%
FCM
32
Farallon Capital Management
California
$1.46M – – –
DCM
33
Dupont Capital Management
Delaware
$1.46M – – –
SC
34
Sculptor Capital
New York
$1.46M – – –
FIG
35
Fortress Investment Group
New York
$1.46M – – –
AR
36
Advisory Research
Illinois
$1.42M – – –
CC
37
Covalis Capital
United Kingdom
$1.22M – – –
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$1.13M +$156K +224 +16%
MCM
39
Moore Capital Management
New York
$975K – – –
ESCM
40
Echo Street Capital Management
New York
$975K +$970K +1,389 New
AC
41
Athos Capital
Hong Kong
$870K – – –
SCM
42
Saba Capital Management
New York
$848K +$305K +437 +57%
HighTower Advisors
43
HighTower Advisors
Illinois
$653K -$28.6K -41 -4%
SCM
44
Segantii Capital Management
Hong Kong
$488K +$485K +694 New
COPPSERS
45
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$487K – – –
NAM
46
Nexpoint Asset Management
Texas
$401K +$400K +572 New
RCM
47
Rivernorth Capital Management
Florida
$390K +$388K +556 New
BCM
48
Basso Capital Management
Connecticut
$372K – – –
CC
49
Centiva Capital
New York
$294K – – –
EC
50
EJF Capital
Virginia
$263K – – –
1
2
3

AEON Hedge Fund Activity: Q3 2021 in Review

59 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q3 2021, worth a combined $172M — up 36% from $126M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new AEON positions and 2 closed out — a net gain of 12 holders — while 7 added to existing stakes and 7 trimmed.

The largest buyer was Empyrean Capital Partners, opening a new position worth an estimated $13.6M. The largest seller was Polar Asset Management Partners, cutting an estimated $2.91M.

  • 59 institutional investors held AEON Biopharma (AEON) as of Q3 2021, up from 47 in Q2 2021.
  • Funds reported $172M of AEON Biopharma stock for Q3 2021, up 36% quarter-over-quarter.
  • 14 funds opened new AEON Biopharma positions in Q3 2021 and 2 closed out, a net change of +12 holders.
  • The largest AEON Biopharma buyer in Q3 2021 was Empyrean Capital Partners, an estimated $13.6M added.
  • The largest AEON Biopharma seller in Q3 2021 was Polar Asset Management Partners, an estimated $2.91M sold.

Based on aggregated 13F filings for Q3 2021.